GSK Rides Cold, Flu And Pain OTCs In Q4 While Allergy Carries Sanofi
Executive Summary
Firm's "power brands" in respiratory and pain areas achieved high single-digit sales growth in the fourth quarter on an “earlier and more severe” cold season that also drove overall consumer health sales in the period up 4.3% to $2.65bn.
You may also be interested in...
Glaxo, Sanofi Look Far Afield For Consumer Health Growth
Big pharmas' recent third-quarter results and commentaries point to sales drivers for consumer health divisions coming from markets outside their established primary markets of US and Europe. Consumer unit lines include oral care and topicals as well as nutritional products.
Glaxo, Sanofi Look Far Afield For Consumer Health Growth
Big pharmas' recent third-quarter results and commentaries point to sales drivers for consumer health divisions coming from markets outside their established primary markets of US and Europe. Consumer unit lines include oral care and topicals as well as nutritional products.
Cough/Cold, Analgesic Patch Sales Ease Pain Of Private Label Growth In OTCs
Topical analgesic sales grew double digits in 2017 on innovation and adhesive patch launches, helping drive 2.1% growth of US manufacturers' OTC drug sales in 2017 to $21.2bn, Kline & Co. independent consultant Laura Mahecha says. But private label continues to outpace branded product sales growth.